ATE165241T1 - Zubereitung enthaltend l-carnitin oder acyl-l- carnitin in kombination mit einem ace-inhibitor zur behandlung von kardiovaskulären störungen - Google Patents

Zubereitung enthaltend l-carnitin oder acyl-l- carnitin in kombination mit einem ace-inhibitor zur behandlung von kardiovaskulären störungen

Info

Publication number
ATE165241T1
ATE165241T1 AT93830120T AT93830120T ATE165241T1 AT E165241 T1 ATE165241 T1 AT E165241T1 AT 93830120 T AT93830120 T AT 93830120T AT 93830120 T AT93830120 T AT 93830120T AT E165241 T1 ATE165241 T1 AT E165241T1
Authority
AT
Austria
Prior art keywords
carnitine
acyl
combination
cardiovascular disorders
treatment
Prior art date
Application number
AT93830120T
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE165241T1 publication Critical patent/ATE165241T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93830120T 1992-03-27 1993-03-26 Zubereitung enthaltend l-carnitin oder acyl-l- carnitin in kombination mit einem ace-inhibitor zur behandlung von kardiovaskulären störungen ATE165241T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920222A IT1254314B (it) 1992-03-27 1992-03-27 Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.

Publications (1)

Publication Number Publication Date
ATE165241T1 true ATE165241T1 (de) 1998-05-15

Family

ID=11400880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93830120T ATE165241T1 (de) 1992-03-27 1993-03-26 Zubereitung enthaltend l-carnitin oder acyl-l- carnitin in kombination mit einem ace-inhibitor zur behandlung von kardiovaskulären störungen

Country Status (11)

Country Link
US (1) US5861434A (de)
EP (1) EP0566542B1 (de)
JP (1) JP3616116B2 (de)
KR (1) KR100244092B1 (de)
AT (1) ATE165241T1 (de)
CA (1) CA2092505C (de)
DE (1) DE69318061T2 (de)
DK (1) DK0566542T3 (de)
ES (1) ES2116429T3 (de)
HK (1) HK1009325A1 (de)
IT (1) IT1254314B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733911B1 (fr) * 1995-05-09 1998-05-29 Takeda Chemical Industries Ltd Composition pharmaceutique pour maladies renales ou cardio-vasculaires
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1284661B1 (it) * 1996-06-06 1998-05-21 Sigma Tau Ind Farmaceuti Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.
PT951909E (pt) 1998-03-19 2004-04-30 Sigma Tau Ind Farmaceuti Composicao combinada que contem uma l-carnitina ou uma alcanoil-l-carnitina um glicosaminoglicano e/ou um seu constituinte
LV12491B (lv) * 1998-10-29 2000-12-20 Ivars KALVIŅŠ Farmaceitiska kompozīcija
CA2350071A1 (en) * 1998-11-11 2000-05-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
US20030206895A1 (en) * 1998-11-13 2003-11-06 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
DE60031171T2 (de) * 2000-01-26 2007-08-23 Astellas Pharma Inc. Ace inhibitor-vasopressin antagonist kombinationen
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
SG193655A1 (en) * 2007-03-21 2013-10-30 Sigma Tau Ind Farmaceuti Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
CN102640350B (zh) * 2009-02-18 2015-02-04 豪沃基金有限责任公司 超材料功率放大器系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
IT1235153B (it) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
IT1224795B (it) * 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1240799B (it) * 1990-03-15 1993-12-17 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti 3-metiltiopropionil l-carnitina ad attivita' sul sistema cardiovascolare.
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
IT1248323B (it) * 1991-05-16 1995-01-05 Sigma Tau Ind Farmaceuti Ammidi con amminoacidi naturali di alcanoil l-carnitine quali inibitori della degenerazione neuronale e attivatori dei processi di apprendimento e memorizzazione e per il trattamento del coma e composizioni farmaceutiche comprendenti tali composti
IT1245699B (it) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi

Also Published As

Publication number Publication date
JPH0616570A (ja) 1994-01-25
IT1254314B (it) 1995-09-14
DE69318061D1 (de) 1998-05-28
ITRM920222A1 (it) 1993-09-27
EP0566542A1 (de) 1993-10-20
EP0566542B1 (de) 1998-04-22
ITRM920222A0 (it) 1992-03-27
CA2092505A1 (en) 1993-09-28
DE69318061T2 (de) 1998-08-13
ES2116429T3 (es) 1998-07-16
JP3616116B2 (ja) 2005-02-02
DK0566542T3 (da) 1999-01-04
KR930019208A (ko) 1993-10-18
CA2092505C (en) 2004-06-01
US5861434A (en) 1999-01-19
KR100244092B1 (ko) 2000-03-02
HK1009325A1 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
ATE165241T1 (de) Zubereitung enthaltend l-carnitin oder acyl-l- carnitin in kombination mit einem ace-inhibitor zur behandlung von kardiovaskulären störungen
GR3035583T3 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE69435086D1 (de) Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen
RU93048466A (ru) Применение бензотиофенов для профилактики и лечения остеопороза и фармацевтическая композиция на их основе
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
ATE142489T1 (de) Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69621012T2 (de) VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
GR3026369T3 (en) Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist.
RU93051537A (ru) Перорально вводимая лекарственная форма
DE69413789D1 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
ATE206916T1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
RO117760B1 (ro) Metodă pentru tratamentul unei afecţiuni de neurotransmisie serotoninergică defectivă
ATE69164T1 (de) Arzneimittel zur behandlung von uraemie.
DE69201660T2 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
JPS57126420A (en) Drug for digestive organ
DE69327314D1 (de) Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
RO117174B1 (ro) Derivaţi nitrobenzamidici, compoziţie farmaceutică şi metodă de tratament şi/sau profilaxie a aritmiei şi tulburărilor ischemice
DE68910010D1 (de) Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin.
DE59608276D1 (de) Verwendung von threonin zur behandlung der phenylketonurie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification